{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=3", "query": { "condition": "Cancer of the Ovary", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2193, "total_pages": 220, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Ovary&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T22:49:56.262Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06171789", "title": "PRO1107 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "GastroEsophageal Cancer", "Non-small Cell Lung Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "GEN1107", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-01-03", "completion_date": "2025-08-18", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171789" }, { "nct_id": "NCT00114166", "title": "Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 81, "start_date": "2005-01", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 78, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 60 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00114166" }, { "nct_id": "NCT01609556", "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2012-06-28", "completion_date": "2018-03-19", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 10, "location_summary": "Fairway, Kansas • Boston, Massachusetts • Detroit, Michigan + 6 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609556" }, { "nct_id": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Endometrial Cancer", "Cervical Cancer", "Ovarian Cancer", "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Adrenocortical Carcinoma", "Uveal Melanoma" ], "interventions": [ { "name": "[111In]-FPI-1547 Injection", "type": "DRUG" }, { "name": "[225Ac]-FPI-1434 Injection multi-dose", "type": "DRUG" }, { "name": "FPI-1175 Infusion", "type": "BIOLOGICAL" }, { "name": "[225Ac]-FPI-1434 Injection single-dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-01-17", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 7, "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746431" }, { "nct_id": "NCT00069160", "title": "Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Neoplasms", "Ovarian Neoplasms", "Cervix Neoplasms", "Renal Neoplasms" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "tariquidar", "type": "DRUG" }, { "name": "99mTc-sestamibi imaging", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2003-09", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2012-10-12", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069160" }, { "nct_id": "NCT03490669", "title": "Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Pancreatic Cancer", "Non Small Cell Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "MSC-1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-05-21", "completion_date": "2019-09-23", "has_results": false, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03490669" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT01248273", "title": "Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tubes", "Ovarian Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2010-11", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248273" }, { "nct_id": "NCT02144051", "title": "Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor" ], "interventions": [ { "name": "AZD5312", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 32, "start_date": "2014-05", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 3, "location_summary": "Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144051" }, { "nct_id": "NCT04537702", "title": "Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ovarian Cancer, Epithelial", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Streamlined Education", "type": "BEHAVIORAL" }, { "name": "Traditional Education", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 64, "start_date": "2019-08-08", "completion_date": "2021-07-31", "has_results": false, "last_update_posted_date": "2021-08-26", "last_synced_at": "2026-10-09T22:49:56.262Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537702" } ] }